What Tienam Treats: Main Uses and Benefits

Quick Fact: Relevant for Systemic Discomfort Management

---

The medication is applied across domains where additional symptomatic support is needed in situations where patients experience severe bacterial infections. Its use is relevant in contexts marked by increased discomfort and is used to manage symptoms that create noticeable physiological strain. The medicine is used in situations involving certain distressing symptoms linked to its core indications.

It is commonly used across conditions presenting with acute episodes of pneumonia, complex intra-abdominal infections, bacteraemia (blood infection), and extensive skin and soft-tissue infections. This therapeutic approach is often used during phases when symptoms become more noticeable due to suspected drug resistance or when the patient is dealing with hospital-acquired infections.

This broad-spectrum approach may assist with maintaining a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes. The therapeutic benefit is relevant for easing symptoms in conditions marked by increased physiological stress, including patient groups who experience neutropenic fever.

Regulatory References

1. Summary of Product Characteristics provided by a government authority

This section summarizes the official rules governing who is eligible to receive Tienam (Imipenem and Cilastatin) as defined by government regulatory agencies.

Contraindicated Populations (Must Not Use)

• Patients with known hypersensitivity to Imipenem, Cilastatin, or any other carbapenem antibacterial agent.
• Individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any other type of beta-lactam antibiotic, such as penicillins or cephalosporins.

Age-Related Eligibility and Restrictions

• Adults and Adolescents: Eligible populations for the medicine.
• Children: Use is established for children 1 year of age and above.
• Infants: The medicine is not recommended for children less than 1 year of age due to insufficient clinical data.

Condition-Specific Limitations

Condition	Regulatory Status
Severe Renal Impairment	Must not be used if Creatinine Clearance is le 5 mL/min/1.73 m^2 unless haemodialysis is instituted within 48 hours.
CNS Disorders	Use requires caution and close monitoring, especially in patients with a history of seizures or brain lesions, due to increased risk of central nervous system adverse reactions.
Pregnancy	Should not be used unless the potential benefit formally justifies the potential risk to the fetus.

Tienam is not recommended for the treatment of meningitis in any age group, nor for pediatric patients with impaired renal function.

Interactions with other medicines and products

Tienam (imipenem/cilastatin) is known to interact with a limited number of medicinal products, leading to effects that may require close monitoring or avoidance of the combination.

Notable Interactions

Interacting Product Category	Specific Interacting Medicines	Interaction Effect and Recommendation
Anticonvulsants	Valproic Acid / Divalproex Sodium	Concomitant use is generally not recommended as it results in a reduction of valproic acid concentrations. This can lead to the antiepileptic drug levels falling below the therapeutic range, thereby increasing the risk of breakthrough seizures.
Antivirals	Ganciclovir	Co-administration is generally not recommended unless the potential benefit significantly outweighs the risk. This caution is based on reports of generalized seizures occurring when these medicines were used together.
Uricosuric Agents	Probenecid	Concomitant administration is not recommended. Probenecid interferes with the kidney's ability to clear imipenem, resulting in elevated plasma levels and a prolonged half-life of imipenem.
Live Vaccines	Cholera Vaccine, Live	Avoid combination. As a systemic antibiotic, Tienam may interfere with the effectiveness of the live vaccine strain, potentially compromising the patient's protection.

Other Relevant Context

Patients with known Central Nervous System (CNS) disorders, such as a history of seizures, may be more susceptible to CNS side effects like myoclonic activity or seizures when receiving Tienam. Appropriate monitoring and consideration of dose adjustment or anticonvulsant therapy may be required in this population.

Tienam is a combination containing two pharmacologically distinct agents: the antibiotic imipenem and the enzyme inhibitor cilastatin. Their combined action establishes a two-pronged mechanistic profile.

---

Inhibition of Bacterial Cell Wall Synthesis

The antibiotic component, imipenem, acts within domains involving enzyme-mediated bacterial processes. It engages key mechanisms by binding to Penicillin-Binding Proteins (PBPs), which are critical enzymes responsible for the synthesis of the peptidoglycan layer of the bacterial cell wall. This binding modifies the early molecular steps of transpeptidation, leading to a crucial biochemical consequence: compromised structural integrity of the bacterial cell, initiating structural collapse and dissolution of the cell.

---

Prevention of Renal Drug Metabolism

Cilastatin modulates a specific metabolic pathway within the human body. It functions as a competitive inhibitor of the human enzyme renal dehydropeptidase-I (DHP-I). DHP-I is responsible for the hydrolysis and subsequent inactivation of imipenem in the kidneys. By inhibiting this enzyme, cilastatin supports the regulation of imipenem's metabolic process. The resulting biochemical consequence is the preservation of imipenem concentration and systemic exposure, ensuring adequate levels of the active antibiotic are maintained for its mechanism of action.

The use of Imipenem and Cilastatin is strictly defined by official instructions, focusing on precise administration via intravenous infusion.

Administration Method and Preparation

This medication is supplied as a sterile powder for solution for infusion and must be administered by the Intravenous (IV) route only. The powder requires mandatory reconstitution and further dilution before use. Each single dose must be infused slowly and steadily into the vein: doses of 500 mg/500 mg or less are administered over 20 to 30 minutes, while larger doses, such as 1000 mg/1000 mg, require a longer infusion period of 40 to 60 minutes. The solution should not be mixed with other drugs in the same infusion container, and specific incompatibilities exist, such as with Ringer lactate.

Official Dosing and Frequency Patterns

The total daily dosage is typically administered in equally divided doses given at intervals of six or eight hours, with the specific regimen determined by factors noted in the prescribing information, and should not exceed a maximum daily limit of 4.0 g of Imipenem/Cilastatin for adults with normal renal function. The duration of the entire treatment course is variable and depends on the specific characteristics of the infection.

Population-Specific Use Constraints

A reduction in dose is necessary for adult patients with impaired renal function, specifically those with a creatinine clearance of le 70 mL/min/1.73 m^2, and for patients weighing less than 70 kg. Patients undergoing haemodialysis should receive their dose after the dialysis session and maintain 12-hour intervals from the end of the session. For pediatric patients (ge 1 year of age), the dose is calculated based on body weight, typically at 15/15 mg/kg or 25/25 mg/kg and administered every six hours.

Tienam: Recent Clinical Evidence

Tienam, a combination of the antibiotic Imipenem and the enzyme inhibitor Cilastatin, has been studied extensively in clinical trials since its introduction. The body of evidence focuses on its activity against a broad range of bacteria, including those that are multi-drug resistant, and its overall safety profile.

---

Spectrum of Activity and Efficacy

Clinical data suggest that Imipenem is associated with a wide spectrum of activity against many Gram-positive and Gram-negative bacteria, as well as anaerobes. Studies have evaluated its use in various severe and complicated infections, including complicated intra-abdominal infections, complicated urinary tract infections, and severe pneumonia.

Initial clinical trials indicated a favorable overall clinical response in a high percentage of patients treated for serious bacterial infections. However, some evidence suggests that resistance to Imipenem, particularly in certain organisms like Pseudomonas aeruginosa and Acinetobacter baumannii, may develop during or after the course of treatment. The use of the combination is often reserved for severe infections or when susceptibility to other antibiotics is a concern.

---

Safety and Tolerability Observations

The most commonly observed clinical adverse events in trials were generally related to the intravenous infusion site or to the gastrointestinal system, such as nausea, vomiting, and diarrhea. Seizures and other central nervous system effects have been reported, primarily in patients with pre-existing central nervous system disorders or compromised kidney function.

Cilastatin's presence in the formulation helps to maintain Imipenem concentrations and may mitigate some potential effects on the kidney, although the overall certainty of this evidence is low and further large-scale trials are needed to confirm a protective effect against acute kidney injury.

Common questions about Tienam (FAQ)

---

Q: What is Tienam used for in adults?

According to the official product information, Tienam is used in adults for treating certain bacterial infections that require antibiotics, particularly those caused by bacteria sensitive to the combination of imipenem and cilastatin. It is used for a variety of serious infections, including complicated intra-abdominal infections and community-acquired pneumonia. Official prescribing information indicates that the use of Tienam is typically considered for severe infections or when other, initial antibiotics may not be appropriate for the specific bacteria identified.

---

Q: What is the active ingredient in Tienam?

Tienam contains two active components: imipenem and cilastatin. Imipenem is the carbapenem antibiotic that works to eliminate the bacteria. Cilastatin is included to prevent the body from rapidly breaking down imipenem, which allows the antibiotic component to remain active and effective in the body for the required duration.

---

Q: Can children be treated with Tienam?

Regulatory documents state that Tienam is used in children aged one year or older for treating some specific severe infections, such as those associated with fever and low white blood cell counts (febrile neutropenia) and complicated intra-abdominal infections. Official information also specifies that its use is contraindicated (not allowed) in children with severe kidney problems.

---

Q: What is the carbapenem class of antibiotics?

Carbapenems are a type of broad-spectrum antibiotic, meaning they are effective against a wide range of different bacteria. Studies and official information indicate that this class of medicine is often reserved for treating serious bacterial infections, especially those that may be resistant to other, more common types of antibiotics. Imipenem, which is one of the components of Tienam, belongs to this classification.

Storage and Disposal Requirements for Tienam

The storage and disposal of Tienam (Imipenem and Cilastatin) powder must strictly adhere to regulatory guidelines to maintain its stability and comply with waste standards.

---

Storage of Unreconstituted Powder

The sterile powder vials must be stored in the original container and kept at a temperature at or below 25 C (77 F). Like all medicines, the product must be kept out of the reach and sight of children.

Stability of Reconstituted Solution

The stability of the solution is time-sensitive and depends on the diluent and temperature. The solution must be used immediately after initial preparation.

Diluent Used	Maximum Stable Period (Refrigerated 2 C to 8 C)	Maximum Stable Period (Room Temperature below 25 C)
0.9% Saline	24 hours	4 hours
5% Dextrose	10 hours	2 hours

Disposal

Unused or expired product and container contents must be disposed of through an approved waste disposal plant in accordance with local pharmaceutical waste regulations. Disposal into wastewater must be avoided.